Yoltech Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Yoltech Therapeutics - overview
Established
2021
Location
Shanghai, Shanghai, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and founded in 2021, Shanghai Yaotang Biotechnology Co. , Ltd. , trading as Yoltech Therapeutics, is a biotech company committed to developing gene-editing drugs against hereditary diseases and cardiovascular diseases. The company's founder, Dr.
Yuxuan Wu, graduated from East China Normal University. In May 2026, Yoltech Therapeutics raised nearly CNY 500 million in series C funding led by Loyal Valley Capital, with participation from Shanghai State-owned Capital Investment Leading Fund, Shanghai Minhang Financial Investment Development, Deyue Investment, K2VC, Grand Flight Investment, Tianjin Venture Capital and other investors. The company focuses on the development of mRNA drugs and gene editing drugs by improving mRNA production platforms and lipid nanocarrier assembly processes through CRISPR, base editing and other gene editing tools. The current pipeline of products in development includes LNP in vitro delivery of gene edited drugs for metabolic diseases (familial hypercholesterolemia, etc.
), genetic diseases (primary hyperoxaluria, etc. ), and infectious diseases (hepatitis B, etc. ). The company's revenue is generated by developing mRNA drugs and gene editing drugs.
Current Investors
K2VC, Unity Ventures, Grand Flight Investment
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.yoltx.com/
Company Stage
Series C
Total Amount Raised
Subscriber access only
Yoltech Therapeutics - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series C | Completed | Yoltech Therapeutics | - | ||||||||
| Series B | Completed | Yoltech Therapeutics | - | ||||||||
| Series A | Completed | Yoltech Therapeutics | - | ||||||||
| Series A | Completed | Yoltech Therapeutics | - | ||||||||
| Angel | Completed | Yoltech Therapeutics | - |
Displaying 1 - 5 of 5
Yoltech Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.